Denovicon uses an innovative combination of machine learning and physics-based modeling to streamline the development of small molecule therapeutics, dramatically reducing R&D timelines and improving clinical success. In a recent blog, Founder and CEO, Scott Bembenek reflects on the challenges of modern-day drug discovery and how Denovicon’s platform is leading the way in the computational/AI drug discovery platform space. In its kickoff project on next-generation PARP1 inhibitors, the platform delivered an unprecedented 80% success rate, followed by a 59% success rate in their first-in-class PARP7 project (both used a high bar of 50% inhibition @ 1µM as the cutoff). Moreover, Bembenek reflects on Denovicon’s strategic collaboration with Biovia and parent company Dassault Systèmes and how the combination of a proprietary platform in combination with enterprise software really is the best of both worlds.
858-692-3573
info@denovicontx.com
